摘要
目的研究非小细胞肺癌(None-small cell lung cancer,NSCLC)患者外周血Runx3基因启动子甲基化的临床意义。方法选择NSCLC患者(NSCLC组)和正常健康人(CON组)为研究对象,检测并比较两组研究对象外周血Runx3基因启动子甲基化,比较外周血Runx3基因启动子甲基化与未甲基化患者R0切除率、3年生存率及总生存时间的差异。结果 NSCLC组患者外周血Runx3基因启动子甲基化率显著高于CON组(P<0.05)。NSCLC组患者外周血Runx3基因启动子甲基化在胸腔积液、分化程度、肿瘤直径、淋巴结转移、远处转移和TNM分期存在明显差异(均P<0.05)。NSCLC组患者Runx3基因启动子甲基化者R0切除率、3年生存率及总生存时间均显著低于未甲基化者(均P<0.05)。结论 NSCLC患者外周血Runx3基因启动子甲基化异常,在病情及预后评估中具有一定临床价值。
Objective To detect the peripheral blood Runx3 gene promoter methylation in non-small cell lung cancer and its clinical value. Methods Methylation specific PCR was used to detect the Runx3 gene promoter methylation by peripheral blood in patient with non-small cell lung cancer （the NSCLC group） and normal healthy people （the control group）. The Runx3 gene promoter methylation rates in different clinicopathological factors were compared. The R0 radical resection, 3-year survival rate and total survival time between patients with Runx3 gene promoter methylation and unmethylation were compared. Results The Runx3 gene promoter methylation rate in the NSCLC group was significantly higher than in the control group （ P 〈 0. 05 ）. The Runx3 gene Promoter methylation rate showed obvious difference in pleural effusion, degree of differentiation, tumor diameter, lymph node metastasis, distant metastasis and TNM staging were significant different （ all P 〈 0.05 ） , but no difference in sex, gender, age and pathological types （ all P 〉 0. 05 ）. The R0 radical resection, 3-year survival rate and total survival time in pa- tients with Runx3 gene promoter methylation were significantly lower than in patients with Runx3 gene promoter un- methylation （ all P 〈 0.05 ）. Conclusion Runx3 gene promoter＇ s hypermethylation has value in the evaluation of non-small cell lung cancer＇ s disease condition and prognosis, which can be used as a bio-marker.
出处
《临床肺科杂志》
2017年第4期608-610,共3页
Journal of Clinical Pulmonary Medicine
